Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 616 clinical trials
Featured trial
ACCL0993: A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infection in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)

ACCL0993: A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infection in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)

  • 130 views
  • 08 Nov, 2020
  • 1 location
Featured trial
Celgene MDS-AML Registry Connect

Celgene MDS-AML Registry Connect

  • 78 views
  • 08 Nov, 2020
  • 1 location
Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years

This study evaluates the effect of different induction courses in children and adolescents with newly diagnosed acute myeloid leukemia. In the first course patients are randomised to receive

  • 26 views
  • 21 Jan, 2021
  • 34 locations
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

This phase II trial studies how stopping tyrosine kinase inhibitors will affect treatment-free remission in patients with chronic myeloid leukemia in chronic phase. When the level of disease is

  • 12 views
  • 04 Oct, 2022
  • 88 locations
A Multi-center, Open-label Study to Determine the Dose and Safety of Oral Asciminib in Pediatric Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP), Previously Treated With One or More Tyrosine Kinase Inhibitors

The aim of this study is to support development of asciminib in the pediatric population (1 to <18 years) previously treated with one or more TKIs. Full extrapolation of the efficacy of asciminib from adult to pediatric patients will be conducted. Full extrapolation is based on the concept that CML …

leukemia
basophils
asciminib
  • 0 views
  • 20 Oct, 2022
  • 24 locations
A Phase 1b Study of JNJ-75276617 in Combination With AML Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of JNJ-75276617 in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of JNJ-75276617 in combination with AML directed therapies at the RP2D(s) (dose expansion).

azacitidine
venetoclax
  • 0 views
  • 20 Oct, 2022
  • 9 locations
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)

-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with

  • 103 views
  • 23 Oct, 2022
  • 16 locations
CC-486 and Venetoclax for Acute Myeloid Leukemia

This is an open label, dose escalation Phase I single institution pilot study for relapsed and refractory AML patients using CC-486 (oral azacitidine) with venetoclax. At the completion of dose escalation and after establishment of the MTD or recommended dose of CC-486 with venetoclax, an expansion phase will commence, using …

  • 0 views
  • 20 Apr, 2022
  • 2 locations
Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia

regrowth and relapse. Moreover, it has been experimentally shown that leukemic cells in acute myeloid leukemia patients who relapse become sensitive to glucocorticoids treatment highlighting a novel

  • 0 views
  • 04 Oct, 2022
  • 5 locations
Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients

This pilot phase II trial studies how well selinexor works when given together with induction, consolidation, and maintenance therapy in treating older patients with acute myeloid leukemia

  • 13 views
  • 05 Jun, 2022
  • 1 location